Abstract:
OBJECTIVE To discuss the rationality of common off-label use in neonates, and to provide a reference for neonates safety and rational administration.
METHODS Medication orders in neonatal department were collected from August 2016 to July 2017, and the rationality of common off-label use evaluated.
RESULTS Off-label use was inevitably, which should be evaluated on the basis of analysis on the presence of evidence-based.
CONCLUSION Clinical pharmacists shall participate in the standard management of off-label use, seek medical evidence actively, and provide scientific and reasonable suggestions to clinicians.